Results 31 to 40 of about 28,869 (265)

Entecavir‐induced neutropenia in an adult living donor liver transplant recipient: Successful conversion to tenofovir alafenamide

Clinical Case Reports, 2023
Key Clinical Message At 22 weeks post‐transplantation for HBV‐related cirrhosis, an adult woman developed neutropenia which was aggravated by COVID‐19 (ANC 0.4 × 109/L). Covid resolution and all “conventional” modifications were ineffective.
I. Vern Lim, Nurgül Özgür Yurttaş, Mesut Ayer, Şule Poturoğlu, Erdem Kınacı, İlgin Özden   +5 more
doaj   +1 more source

Prospective study to assess progression of renal markers after interruption of tenofovir due to nephrotoxicity [PDF]

, 2016
Background. Prospective studies about the reversibility of tenofovir disoproxil fumarate- (TDF-) related renal impairment remain scarce. Methods. This is an observational prospective study including all patients that presented at our HIV Unit who ...
Bonjoch Badia, Anna, Clotet Sala, Bonaventura, Echeverria Liras, Patricia, Estany Quera, Carla, Negredo Puigmal, Eugènia, Puig, Jordi, Pérez Álvarez, Nuria   +6 more
core   +5 more sources

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population

CPT: Pharmacometrics & Systems Pharmacology, 2023
Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are prodrugs of the nucleotide analogue tenofovir, which acts intracellularly to inhibit HIV replication.
Aida N. Kawuma, Roeland E. Wasmann, Phumla Sinxadi, Simiso M. Sokhela, Nomathemba Chandiwana, Willem D. F. Venter, Lubbe Wiesner, Gary Maartens, Paolo Denti   +8 more
doaj   +1 more source

Stability-indicating method development and validation for the concurrent determination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide by UPLC in bulk and tablet dosage forms

Future Journal of Pharmaceutical Sciences, 2021
Background Tablet dosage forms containing combination of darunavir a protease inhibitor, cobicistat a cytochrome P450 3A inhibitor, emtricitabine and tenofovir alafenamide which were nucleoside reverse transcriptase inhibitors were approved by USFDA on ...
M. Satya Venkata Sakuntala, A. Lakshmana Rao, M. William Carey   +2 more
doaj   +1 more source

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide

Drugs in Context, 2021
Although tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have been evaluated in various clinical trials, limited safety and efficacy data exist in real-world settings.
Sarah M Michienzi, Mikayla Johnson, Thomas D Chiampas, Eric Wenzler, Rodrigo M Burgos, Renata O Smith, Melissa E Badowski   +6 more
doaj   +1 more source

The role of drug transporters in the kidney: lessons from tenofovir [PDF]

, 2014
Tenofovir disoproxil fumarate, the prodrug of nucleotide reverse transcriptase inhibitor tenofovir, shows high efficacy and relatively low toxicity in HIV patients.
Moss, DM, Neary, M, Owen, A
core   +2 more sources

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide

Journal of the International Association of Providers of AIDS Care, 2020
HIV is a serious chronic medical condition. Significant improvements in antiretroviral therapy have led to a transformation in its management. No curative treatment is available for HIV, and lifelong therapy is required with a combination of agents to ...
Chanie Wassner PharmD, BCCCP, BCIDP, Nicole Bradley PharmD, BCPS, BCIDP, Yuman Lee PharmD, BCIDP, AAHIVP   +2 more
doaj   +1 more source

Bictegravir, Emtricitabine & Tenofovir Alafenamide-associated Acute Pancreatitis

Translation, 2023
Please view the PDF to see the formatted meeting abstract.
Abdulmajeed Alharbi
doaj   +1 more source

ProTides for Antiviral Activity Beyond Liver Cells

Chemistry – A European Journal, EarlyView.
A strategy for obtaining prodrugs of antiviral nucleotides with broad tissue activity is presented that relies on cycloalkyl or cycloalkylalkyl esters, improving uptake and esterase cleavage, and producing nanomolar inhibitors in kidney, colon, and lung cells.
Felix Goebel, Adrian Humboldt, Heeyoung Kim, Carl J. M. Schölzel, Ralf Bartenschlager, Clemens Richert   +5 more
wiley   +1 more source

A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection [PDF]

, 2014
A number of antiviral agents used against Human Immunodeficiency Virus (HIV) infection and hepatitis B virus (HBV) mono or co-infection have been associated with real nephrotoxicity (including tenofovir disoproxil fumarate (TDF), atazanavir, indinavir ...
Abbas, R., Baer, R., Boyd, M., Gracey, D., Holt, S., Irish, A., Levy, M., Mudge, D., Sevastos, J., Walker, R.   +9 more
core   +3 more sources